Skip to main content

ADVERTISEMENT

Maria Asimopoulos

News
01/18/2023
Maria Asimopoulos
The Centers for Medicare & Medicaid Services announced the Medicare Shared Savings Program, ACO REACH, and Kidney Care Choices Model will grow in 2023.
The Centers for Medicare & Medicaid Services announced the Medicare Shared Savings Program, ACO REACH, and Kidney Care Choices Model will grow in 2023.
The Centers for Medicare &...
01/18/2023
First Report Managed Care
Headshot of Gregg Miller, MD, Vituity, on a blue background underneath the PopHealth Perspectives logo.
Podcasts
01/17/2023
Maria Asimopoulos
Gregg Miller, MD, chief medical officer, Vituity, offers his insights on how the combination of COVID-19, respiratory syncytial virus, and influenza is hitting health systems, as well as what actions can be taken to promote provider wellness...
Gregg Miller, MD, chief medical officer, Vituity, offers his insights on how the combination of COVID-19, respiratory syncytial virus, and influenza is hitting health systems, as well as what actions can be taken to promote provider wellness...
Gregg Miller, MD, chief medical...
01/17/2023
Integrated Healthcare Executive
News
01/17/2023
Maria Asimopoulos
In addition to illuminating ongoing barriers, the report showed payers’ drug coverage policies largely were aligned with fair access criteria.
In addition to illuminating ongoing barriers, the report showed payers’ drug coverage policies largely were aligned with fair access criteria.
In addition to illuminating...
01/17/2023
First Report Managed Care
News
01/13/2023
Maria Asimopoulos
Hospitalization rates and lengths of stay went down after patients received gene replacement therapy, according to the findings.
Hospitalization rates and lengths of stay went down after patients received gene replacement therapy, according to the findings.
Hospitalization rates and...
01/13/2023
First Report Managed Care
News
01/12/2023
Maria Asimopoulos
Researchers followed patients with spinal muscular atrophy type 2 and type 3 for up to 38 months to evaluate a treatment’s efficacy in relation to motor function and disease progression.
Researchers followed patients with spinal muscular atrophy type 2 and type 3 for up to 38 months to evaluate a treatment’s efficacy in relation to motor function and disease progression.
Researchers followed patients...
01/12/2023
First Report Managed Care
Headshots of 14 leaders in health care
Commentary
01/10/2023
Maria Asimopoulos
After a year of inflation, staffing struggles, and challenges related to addressing social determinants of health, 14 executives from health care organizations predict where the industry is headed in 2023.
After a year of inflation, staffing struggles, and challenges related to addressing social determinants of health, 14 executives from health care organizations predict where the industry is headed in 2023.
After a year of inflation,...
01/10/2023
Integrated Healthcare Executive
News
01/06/2023
Maria Asimopoulos
Lecanemab is the second drug targeting the underlying pathophysiology of Alzheimer disease to receive approval.
Lecanemab is the second drug targeting the underlying pathophysiology of Alzheimer disease to receive approval.
Lecanemab is the second drug...
01/06/2023
First Report Managed Care
News
01/06/2023
Maria Asimopoulos
The policy is intended to increase Medicaid and CHIP beneficiaries’ access to specialty care by way of interprofessional consultations.
The policy is intended to increase Medicaid and CHIP beneficiaries’ access to specialty care by way of interprofessional consultations.
The policy is intended to...
01/06/2023
First Report Managed Care
News
01/03/2023
Maria Asimopoulos
In addition to determining the link between regimen complexity and A1c, researchers recommended strategies for improving outcomes in underserved populations.
In addition to determining the link between regimen complexity and A1c, researchers recommended strategies for improving outcomes in underserved populations.
In addition to determining the...
01/03/2023
Pharmacy Learning Network
Headshot of John Fryer, Tribus and Lumeris
Interview
01/03/2023
Maria Asimopoulos
John Fryer, president, Tribus, and senior vice president of national markets, Lumeris, offers insight into challenges providers have come up against when switching from fee-for-service to value-based payment models and shares how accelerated...
John Fryer, president, Tribus, and senior vice president of national markets, Lumeris, offers insight into challenges providers have come up against when switching from fee-for-service to value-based payment models and shares how accelerated...
John Fryer, president, Tribus,...
01/03/2023
Integrated Healthcare Executive